Our diagnostic solutions provide clinicians novel tools to estimate cancer aggressivity at the time of diagnosis and help them to select the most effective, and health economical therapies. 

CURRENT TARGET DISEASE
Head and neck squamous cell carcinoma (HNSCC) 
Almost one million new cases annually
50% mortality rate
No improvement in survival rate over the decades
Lack of diagnostic method to identify deadly cancer cases

BENEFITS FOR:
CLINICIANS AND HOSPITALS
Novel, accurate tool for diagnosis and prognosis
Facilitated decision-making
Cost savings
PATIENTS
Less side-effects
Better quality of life through accurate diagnosis and personalised treatment


THESTRA SOLUTION:
Patented EPLINEx™ solution for identification of HNSCC cases that are life threatening. 
Artificial intelligence based HNSCC tissue analysis. 



Thestra

Org chart

Teams

Offices